Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04839523 · ClinicalTrials.gov registry record · NA
Performance and Safety of Exufiber Ag+ and Exufiber on Partial Thickness Burns
A NA study of Partial-thickness Burn, sponsored by Molnlycke Health Care AB.
- Active
- Registry status
- NA
- Development phase
- 44
- Enrollment target
- 6
- Study locations
NCT04839523: Active NA study of Partial-thickness Burn, sponsored by Molnlycke Health Care AB.
NCT04839523 is a NA study of Partial-thickness Burn that is active but no longer recruiting, run by Molnlycke Health Care AB. The registered enrollment target is 44 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04839523, a NA study of Partial-thickness Burn, is active but no longer recruiting, sponsored by Molnlycke Health Care AB.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 44 participants
- Enrollment target
- 6
- Study locations
Study Summary
This a multi-center, open label, non-comparative, study that will evaluate the clinical safety and performance of Exufiber Ag+ and Exufiber dressings, separately, when used as intended in moderate to high exuding partial thickness burns (PTBs) through assessment of wound progression from baseline to the Subject's last clinical follow-up visit. Sixty-eight (68) eligible subjects, with moderate to high exuding partial-thickness burns, will be selected for treatment with either Exufiber Ag+ silver-coated gelling dressing, or Exufiber gelling dressing. The study will last 5 weeks, with a requirement of 5 study visits in total, including dressing changes at each study visit.
Primary Outcome
A subjective measurement to determine wound progression since the last visit, determined by three outcome variables: Deteriorated No Change Improved
Conditions Studied
Interventions
- DEVICE Exufiber
- DEVICE Exufiber Ag+
Study Locations (6)
Arizona
- Arizona Burn Center, Valleywise Health - Phoenix
California
- Keck Medical Center of USC - Los Angeles
District of Columbia
- MedStar Health Research Institute - Washington D.C.
Florida
- University of South Florida-Tampa General Hospital - Tampa
Massachusetts
- Massachusetts General Hospital - Boston
Pennsylvania
- Drexel Univerisity - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2021-03-10 |
| Est. Completion | 2024-12-31 |
| Phase | NA |
What the registry record for NCT04839523 still lists
NCT04839523 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Partial-thickness Burn appearing as the primary indexed condition, and to 2 interventions - of which Exufiber is the first listed.
NCT04839523 lists 6 locations in 6 states (Arizona, California, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT04839523 about?
NCT04839523 is a clinical study titled "Performance and Safety of Exufiber Ag+ and Exufiber on Partial Thickness Burns". This a multi-center, open label, non-comparative, study that will evaluate the clinical safety and performance of Exufiber Ag+ and Exufiber dressings, separately, when used as intended in moderate to high exuding partial thickness burns (PTBs) through assessment of wound progression from baseline to...
What is the current status of trial NCT04839523?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 44 participants. The study started on 2021-03-10. Estimated completion is 2024-12-31.
What conditions does trial NCT04839523 study?
This clinical trial studies the following conditions: Partial-thickness Burn.
What interventions are being tested in trial NCT04839523?
The interventions under investigation include: Exufiber (DEVICE), Exufiber Ag+ (DEVICE).
Who is sponsoring clinical trial NCT04839523?
This trial is sponsored by Molnlycke Health Care AB, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04839523 being conducted?
This trial has 6 study locations across Arizona, California, District of Columbia, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Partial-thickness Burn
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04839523's enrollment target sits among peer trials
44 1423rd of 2000 higher than 566 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI